Vildagliptin/metformin: Difference between revisions
Content deleted Content added
←Created page with '{{Infobox drug | drug_name = | type = combo | component1 = Vildagliptin | class1 = Dipeptidyl peptidase-4 inhibitor |...' |
No edit summary |
||
| Line 23: | Line 23: | ||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
||
| legal_NZ = <!--Class A, B, C --> |
| legal_NZ = <!--Class A, B, C --> |
||
| legal_status = |
| legal_status = Rx-only |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| Line 34: | Line 34: | ||
}} |
}} |
||
'''Vildagliptin/metformin''' (trade names '''Eucreas''' and '''Galvumet''') is a [[combination drug]] for the treatment of [[type 2 diabetes]]. It was approved by the [[European Medicines Agency]] in 2008.<ref name=reuters_eucreas>{{Cite web | title = EU approves Novartis's Eucreas diabetes drug | url = https://www.reuters.com/article/companyNews/idUSZAT00747520080225 | publisher = Reuters | date = February 25, 2008}}</ref> It combines 50 mg [[vildagliptin]] with either 500, 850, or 1000 mg [[metformin]].<ref>{{cite web | url = https://www.news-medical.net/drugs/Galvumet.aspx | title = Galvumet}}</ref> |
'''Vildagliptin/metformin''' (trade names '''Eucreas''' and '''Galvumet''') is a [[combination drug]] for the treatment of [[type 2 diabetes]].<ref>{{Cite journal | pmc = 2515409}}</ref> It was approved by the [[European Medicines Agency]] in 2008.<ref name=reuters_eucreas>{{Cite web | title = EU approves Novartis's Eucreas diabetes drug | url = https://www.reuters.com/article/companyNews/idUSZAT00747520080225 | publisher = Reuters | date = February 25, 2008}}</ref> It combines 50 mg [[vildagliptin]] with either 500, 850, or 1000 mg [[metformin]].<ref>{{cite web | url = https://www.news-medical.net/drugs/Galvumet.aspx | title = Galvumet}}</ref> |
||
==References== |
==References== |
||
Revision as of 14:32, 29 July 2018
| Combination of | |
|---|---|
| Vildagliptin | Dipeptidyl peptidase-4 inhibitor |
| Metformin | Biguanide antihyperglycemic agent |
| Clinical data | |
| Trade names | Eucreas, Galvumet |
| Legal status | |
| Legal status |
|
Vildagliptin/metformin (trade names Eucreas and Galvumet) is a combination drug for the treatment of type 2 diabetes.[1] It was approved by the European Medicines Agency in 2008.[2] It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin.[3]
References
- ^ . PMC 2515409 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515409.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ "EU approves Novartis's Eucreas diabetes drug". Reuters. February 25, 2008.
- ^ "Galvumet".
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |